See more : Southern First Bancshares, Inc. (SFST) Income Statement Analysis – Financial Results
Complete financial analysis of Agios Pharmaceuticals, Inc. (0HB0.L) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Agios Pharmaceuticals, Inc., a leading company in the Medical – Pharmaceuticals industry within the Healthcare sector.
- Lexaria Bioscience Corp. (LEXX) Income Statement Analysis – Financial Results
- StorageVault Canada Inc. (SVI.TO) Income Statement Analysis – Financial Results
- Icon Energy Limited (ICNOF) Income Statement Analysis – Financial Results
- Okabe Co., Ltd. (5959.T) Income Statement Analysis – Financial Results
- Manaris (2010) Corp. (AVNY) Income Statement Analysis – Financial Results
Agios Pharmaceuticals, Inc. (0HB0.L)
About Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 26.82M | 14.24M | 0.00 | 0.00 | 117.91M | 94.39M | 43.01M | 69.89M | 59.12M | 65.36M | 25.55M | 25.11M |
| Cost of Revenue | 9.50M | 20.26M | 18.78M | 18.77M | 17.94M | 8.57M | 292.68M | 220.16M | 141.83M | 100.37M | 54.50M | 41.04M |
| Gross Profit | 17.32M | -6.02M | -18.78M | -18.77M | 99.98M | 85.82M | -249.67M | -150.27M | -82.71M | -35.01M | -28.95M | -15.93M |
| Gross Profit Ratio | 64.57% | -42.30% | 0.00% | 0.00% | 84.79% | 90.92% | -580.48% | -215.00% | -139.90% | -53.57% | -113.33% | -63.45% |
| Research & Development | 288.90M | 271.35M | 247.73M | 211.02M | 402.81M | 341.32M | 292.68M | 220.16M | 141.83M | 100.37M | 54.50M | 41.04M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 35.99M | 19.12M | 9.93M | 7.06M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -3.34M | 0.00 | 0.00 | 0.00 |
| SG&A | 119.90M | 111.68M | 111.91M | 106.12M | 123.50M | 106.97M | 64.69M | 45.01M | 32.65M | 19.12M | 9.93M | 7.06M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 408.81M | 383.02M | 359.64M | 317.14M | 526.31M | 448.30M | 357.37M | 265.17M | 174.48M | 19.12M | 9.93M | 7.06M |
| Cost & Expenses | 418.31M | 403.29M | 378.42M | 335.92M | 544.25M | 456.87M | 363.81M | 270.88M | 177.82M | 119.49M | 64.43M | 48.10M |
| Interest Income | 33.34M | 12.79M | 836.00K | 6.61M | 14.86M | 16.45M | 6.12M | 2.51M | 968.00K | 203.00K | 55.00K | 69.00K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 17.83M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 6.62M | 18.56M | 18.78M | 18.77M | 16.62M | 7.17M | 6.43M | 5.71M | 3.34M | 1.37M | 1.44M | 1.18M |
| EBITDA | -345.47M | -213.24M | -337.73M | -310.53M | -394.85M | -355.31M | -314.36M | -195.28M | -115.36M | -52.77M | -37.44M | -21.82M |
| EBITDA Ratio | -1,287.94% | -2,601.74% | 0.00% | 0.00% | -347.47% | -376.44% | -730.89% | -279.40% | -195.13% | -80.73% | -146.56% | -86.90% |
| Operating Income | -391.49M | -389.05M | -378.42M | -335.92M | -426.33M | -362.48M | -320.79M | -200.99M | -118.70M | -54.13M | -38.88M | -23.00M |
| Operating Income Ratio | -1,459.52% | -2,732.07% | 0.00% | 0.00% | -361.57% | -384.03% | -745.84% | -287.57% | -200.78% | -82.83% | -152.20% | -91.59% |
| Total Other Income/Expenses | 39.40M | 157.25M | 21.91M | 6.61M | 124.93M | 16.45M | 6.12M | 2.51M | 968.00K | 203.00K | 55.00K | 69.00K |
| Income Before Tax | -352.09M | -231.80M | -356.51M | -329.31M | -411.47M | -346.03M | -314.67M | -198.47M | -117.73M | -53.93M | -38.83M | -22.93M |
| Income Before Tax Ratio | -1,312.63% | -1,627.82% | 0.00% | 0.00% | -348.97% | -366.61% | -731.60% | -283.97% | -199.14% | -82.51% | -151.98% | -91.32% |
| Income Tax Expense | 0.00 | 0.00 | 27.91M | -1.94M | 0.00 | 7.01M | 0.00 | 0.00 | 0.00 | 426.00K | 579.00K | 2.82M |
| Net Income | -352.09M | -231.80M | -384.42M | -327.37M | -411.47M | -346.03M | -314.67M | -198.47M | -117.73M | -53.50M | -43.57M | -27.29M |
| Net Income Ratio | -1,312.63% | -1,627.82% | 0.00% | 0.00% | -348.97% | -366.61% | -731.60% | -283.97% | -199.14% | -81.86% | -170.54% | -108.71% |
| EPS | -6.33 | -4.23 | -6.36 | -4.74 | -6.86 | -6.03 | -6.75 | -5.07 | -3.15 | -1.59 | -2.83 | -8.02 |
| EPS Diluted | -6.33 | -4.23 | -6.36 | -4.74 | -6.86 | -6.03 | -6.75 | -5.07 | -3.15 | -1.59 | -2.83 | -8.02 |
| Weighted Avg Shares Out | 55.65M | 54.79M | 60.45M | 69.00M | 59.99M | 57.42M | 46.59M | 39.13M | 37.43M | 33.67M | 15.42M | 3.40M |
| Weighted Avg Shares Out (Dil) | 55.65M | 54.79M | 60.45M | 69.00M | 59.99M | 57.42M | 46.59M | 39.13M | 37.43M | 33.67M | 15.42M | 3.40M |
Source: https://incomestatements.info
Category: Stock Reports